Kanaph Therapeutics

At a glance

Kanaph Therapeutics filed 44 disclosures in the last 12 months, including 16 insider and 6 5% holder. The most recent key filing was on Sep 18.

Revenue for 2025 was ₩5.6B, up 30.8% on 2024. It made an operating loss of ₩4.3B. Debt was 25% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩153.1M and operating loss of ₩10.1B.

The 2025 annual report lists 23 employees with an average tenure of 3.6 years and average pay of ₩55.1M. Its 5 directors and auditors were paid ₩126M each on average. It paid no cash dividend for 2025. 이병철 and related parties held 20.41% at year end.

From the 2025 annual report

Staff: 23 (5 men, 18 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩1.3B. Directors and auditors: 5, paid ₩628M in total.

No cash dividend was paid for 2025.

Largest shareholder

이병철 holds 14.40%; with 4 related parties the group holds 20.41% of common shares at year end (from 23.85% at the start of the year).

Auditor: 한울회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary